The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
An analysis of naturally occurring alleles in the lipoprotein lipase pathway found that they and LDL-C-linked alleles affect disease risk independently.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
